Loading clinical trials...
Loading clinical trials...
Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day
Conditions
Interventions
Ibrexafungerp
Locations
1
United States
Woodland Research Northwest (WRN)
Rogers, Arkansas, United States
Start Date
July 12, 2023
Primary Completion Date
November 1, 2023
Completion Date
November 1, 2023
Last Updated
August 8, 2025
NCT06983041
NCT07303101
NCT06835361
NCT05908682
NCT06474247
NCT06397248
Lead Sponsor
Scynexis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions